Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DOVA Dova Pharmaceuticals	$28.04	$28.04	$5.62 ▼ $28.54	$807.55M	2.74	499,313 shs	35,036 shs
EGRX Eagle Pharmaceuticals	$2.36 -18.6%	$2.12	$1.50 ▼ $2.95	$30.65M	0.83	8,612 shs	823 shs
RYTM Rhythm Pharmaceuticals	$65.44 +3.6%	$62.50	$40.46 ▼ $69.89	$4.16B	2.3	553,836 shs	958,500 shs
VNDA Vanda Pharmaceuticals	$4.68 -0.8%	$4.40	$3.81 ▼ $6.37	$275.79M	0.66	611,035 shs	335,590 shs
ZIOP ZIOPHARM Oncology		$1.08	$0.77 ▼ $5.95	$187.12M	1.71	2.01 million shs	2.13 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DOVA Dova Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
EGRX Eagle Pharmaceuticals	0.00%	+3.94%	+52.63%	+87.10%	-48.21%
RYTM Rhythm Pharmaceuticals	+0.73%	+1.71%	+2.98%	+26.38%	+53.90%
VNDA Vanda Pharmaceuticals	-1.26%	+5.59%	+7.52%	+4.89%	-16.46%
ZIOP ZIOPHARM Oncology	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DOVA Dova Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	2.2345 of 5 stars	0.0	3.0	0.0	3.9	0.0	3.3	0.0
RYTM Rhythm Pharmaceuticals	3.8951 of 5 stars	3.5	2.0	0.0	4.3	1.9	0.8	0.6
VNDA Vanda Pharmaceuticals	4.6274 of 5 stars	3.8	2.0	0.0	4.2	2.2	3.3	1.3
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DOVA Dova Pharmaceuticals	0.00	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	0.00	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	3.00	Buy	$77.31	18.14% Upside
VNDA Vanda Pharmaceuticals	3.50	Strong Buy	$16.50	252.56% Upside
ZIOP ZIOPHARM Oncology	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest VNDA, DOVA, ZIOP, EGRX, and RYTM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	RYTM Rhythm Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$84.00
5/29/2025	RYTM Rhythm Pharmaceuticals	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$78.00 ➝ $94.00
5/14/2025	VNDA Vanda Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$13.00
5/13/2025	VNDA Vanda Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/7/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$66.00 ➝ $72.00
5/7/2025	VNDA Vanda Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/8/2025	RYTM Rhythm Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$66.00 ➝ $66.00
4/8/2025	RYTM Rhythm Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$81.00 ➝ $92.00
4/8/2025	RYTM Rhythm Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $80.00
4/7/2025	RYTM Rhythm Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$80.00 ➝ $91.00
4/7/2025	RYTM Rhythm Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$63.00 ➝ $63.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DOVA Dova Pharmaceuticals	$10.35M	78.02	N/A	N/A	$2.71 per share	10.35
EGRX Eagle Pharmaceuticals	$257.55M	0.12	$5.90 per share	0.40	N/A	∞
RYTM Rhythm Pharmaceuticals	$130.13M	31.99	N/A	N/A	$0.35 per share	186.97
VNDA Vanda Pharmaceuticals	$198.77M	1.39	N/A	N/A	$9.24 per share	0.51
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	$0.58 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DOVA Dova Pharmaceuticals	-$72.28M	-$2.60	N/A	N/A	N/A	-544.09%	-101.60%	-67.21%	N/A
EGRX Eagle Pharmaceuticals	$35.64M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	-$260.60M	-$2.81	N/A	N/A	N/A	-123.26%	-739.62%	-44.27%	8/5/2025 (Estimated)
VNDA Vanda Pharmaceuticals	-$18.90M	-$0.75	N/A	N/A	N/A	-21.98%	-8.30%	-6.85%	7/30/2025 (Estimated)
ZIOP ZIOPHARM Oncology	-$79.98M	-$0.43	N/A	N/A	N/A	N/A	-92.84%	-72.46%	N/A

Latest VNDA, DOVA, ZIOP, EGRX, and RYTM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/7/2025	Q1 2025	RYTM Rhythm Pharmaceuticals	-$0.69	-$0.81	-$0.12	-$0.81	$40.43 million	$37.72 million
5/7/2025	Q1 2025	VNDA Vanda Pharmaceuticals	-$0.55	-$0.50	+$0.05	-$0.50	$45.13 million	$50.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DOVA Dova Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
VNDA Vanda Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ZIOP ZIOPHARM Oncology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DOVA Dova Pharmaceuticals	0.41	5.64	5.37
EGRX Eagle Pharmaceuticals	N/A	N/A	N/A
RYTM Rhythm Pharmaceuticals	N/A	3.30	3.13
VNDA Vanda Pharmaceuticals	N/A	3.93	3.91
ZIOP ZIOPHARM Oncology	0.18	3.43	3.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DOVA Dova Pharmaceuticals	33.03%
EGRX Eagle Pharmaceuticals	85.36%
RYTM Rhythm Pharmaceuticals	N/A
VNDA Vanda Pharmaceuticals	88.14%
ZIOP ZIOPHARM Oncology	51.03%

Insider Ownership

Company	Insider Ownership
DOVA Dova Pharmaceuticals	60.30%
EGRX Eagle Pharmaceuticals	28.90%
RYTM Rhythm Pharmaceuticals	6.10%
VNDA Vanda Pharmaceuticals	8.90%
ZIOP ZIOPHARM Oncology	5.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DOVA Dova Pharmaceuticals	115	28.80 million	N/A	Optionable
EGRX Eagle Pharmaceuticals	100	12.99 million	9.23 million	No Data
RYTM Rhythm Pharmaceuticals	140	63.62 million	59.74 million	Optionable
VNDA Vanda Pharmaceuticals	290	58.93 million	53.69 million	Optionable
ZIOP ZIOPHARM Oncology	105	216.15 million	204.91 million	Optionable

VNDA, DOVA, ZIOP, EGRX, and RYTM Headlines

Recent News About These Companies

TCRT stock touches 52-week low at $1.62 amid market challenges

January 30, 2025 | msn.com

Best Global Universities for Oncology

September 11, 2024 | usnews.com

FDA fast-tracks Merck's cancer blockbuster-in-waiting

July 28, 2024 | pharmaphorum.comP

BMS signs $475m cancer immunotherapy deal with Dragonfly

July 23, 2024 | pharmaphorum.comP

Childhood Cancers

February 17, 2024 | curetoday.comC

Alx Oncology Holdings (ALXO)

February 10, 2024 | investing.com

Pediatric Hematology-Oncology Fellowship

February 5, 2024 | bcm.eduB

Alaunos Therapeutics: Other Events, Financial Statements And Exhibits

January 31, 2024 | cbonds.comC

CG Oncology Inc

January 31, 2024 | reuters.com

Oncology Nurses' Narratives About Ethical Dilemmas and Prognosis-Related Communication in Advanced Cancer Patients

December 21, 2023 | medscape.comM

Immuno-Oncology

December 19, 2023 | ajmc.comA

Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?

December 18, 2023 | markets.businessinsider.com

Exploring Patient-Centered Handoffs in Surgical Oncology

December 10, 2023 | medscape.comM

Association of Community Cancer Centers

October 14, 2023 | ajmc.comA

Oncology News and Research

September 19, 2023 | news-medical.netN

WBSPH 2024 - Oncology

September 15, 2023 | newsweek.comN

Kris on Oncology

September 6, 2023 | medscape.comM

Gauging Ziopharm's Chances for Positive Sarcoma Drug Trial Results

August 29, 2023 | thestreet.com

Oncology Cases & Quizzes

August 14, 2023 | medscape.comM

Ziopharm’s palifosfamide fails in first-line STS…

June 20, 2023 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNDA, DOVA, ZIOP, EGRX, and RYTM Company Descriptions

Dova Pharmaceuticals NASDAQ:DOVA

Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.

Eagle Pharmaceuticals NASDAQ:EGRX

$2.36 -0.54 (-18.62%)

As of 01:19 PM Eastern

Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.

Rhythm Pharmaceuticals NASDAQ:RYTM

$65.44 +2.25 (+3.56%)

Closing price 04:00 PM Eastern

Extended Trading

$65.47 +0.03 (+0.05%)

As of 04:59 PM Eastern

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Vanda Pharmaceuticals NASDAQ:VNDA

$4.68 -0.04 (-0.85%)

Closing price 04:00 PM Eastern

Extended Trading

$4.72 +0.04 (+0.75%)

As of 06:49 PM Eastern

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

ZIOPHARM Oncology NASDAQ:ZIOP

ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time